Jahja, R, Huijbregts, SC, de Sonneville, LM, van der Meere, JJ, van Spronsen, FJ. Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria. J Pediatr
2014; 164: 895–899.
Rocha, JC, Martins, MJ. Oxidative stress in phenylketonuria: future directions. J Inherit Metab Dis
2012; 35: 381–398.
Schulpis, KH, Papassotiriou, I, Tsakiris, S, Vounatsou, M, Chrousos, GP. Increased plasma adiponectin concentrations in poorly controlled patients with phenylketonuria normalize with a strict diet: evidence for catecholamine-mediated adiponectin regulation and a complex effect of phenylketonuria diet on atherogenesis risk factors. Metabolism
2005; 54: 1350–1355.
Okano, Y, Nagasaka, H. Optimal serum phenylalanine for adult patients with phenylketonuria. Mol Genet Metab
2013; 110: 424–430.
Sanayama, Y, Nagasaka, H, Takayanagi, M, et al. Experimental evidence that phenylalanine is strongly associated to oxidative stress in adolescents and adults with phenylketonuria. Mol Genet Metab
2011; 103: 220–225.
Nagasaka, H, Tsukahara, H, Okano, Y, et al. Changes of lipoproteins in phenylalanine hydroxylase-deficient children during the first year of life. Clin Chim Acta
2014; 433C: 1–4.
Rocha, JC, van Spronsen, FJ, Almeida, MF, et al. Dietary treatment in phenylketonuria does not lead to increased risk of obesity or metabolic syndrome. Mol Genet Metab
2012; 107: 659–663.
Colomé, C, Artuch, R, Lambruschini, N, Cambra, FJ, Campistol, J, Vilaseca, M. Is there a relationship between plasma phenylalanine and cholesterol in phenylketonuric patients under dietary treatment?
2001; 34: 373–376.
Schulpis, KH, Karikas, GA, Papakonstantinou, E. Homocysteine and other vascular risk factors in patients with phenylketonuria on a diet. Acta Paediatr
2002; 91: 905–909.
Ait-Oufella, H, Sage, AP, Mallat, Z, Tedgui, A. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ Res
2014; 114: 1640–1660.
Perk, J, De Backer, G, Gohlke, H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med
2012; 19: 403–488.
Li, S, Chen, W, Srinivasan, SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA
2003; 290: 2271–2276.
Raitakari, OT, Juonala, M, Kähönen, M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the cardiovascular risk in young finns study. JAMA
2003; 290: 2277–2283.
Agostoni, C, Scaglioni, S, Bonvissuto, M, Bruzzese, MG, Giovannini, M, Riva, E. Biochemical effects of supplemented long-chain polyunsaturated fatty acids in hyperphenylalaninemia. Prostaglandins Leukot Essent Fatty Acids
2001; 64: 111–115.
Nagasaka, H, Okano, Y, Kimura, A, et al. Oxysterol changes along with cholesterol and vitamin D changes in adult phenylketonuric patients diagnosed by newborn mass-screening. Clin Chim Acta
2013; 416: 54–59.
Schulpis, KH, Karakonstantakis, T, Bartzeliotou, A, Karikas, GA, Papassotiriou, I. The association of serum lipids, lipoproteins and apolipoproteins with selected trace elements and minerals in phenylketonuric patients on diet. Clin Nutr
2004; 23: 401–407.
Schulpis, KH, Bartzeliotou, A, Tsakiris, S, Gounaris, A, Papassotiriou, I. Serum paraoxonase/arylesterase activities in phenylketonuric patients on diet. Eur J Clin Nutr
2007; 61: 803–808.
Lucock, M, Yates, Z, Hall, K, et al. The impact of phenylketonuria on folate metabolism. Mol Genet Metab
2002; 76: 305–312.
Huemer, M, Födinger, M, Bodamer, OA, et al. Total homocysteine, B-vitamins and genetic polymorphisms in patients with classical phenylketonuria. Mol Genet Metab
2008; 94: 46–51.
Huemer, M, Simma, B, Mayr, D, et al. Free asymmetric dimethylarginine (ADMA) is low in children and adolescents with classical phenylketonuria (PKU). J Inherit Metab Dis
2012; 35: 817–821.
Colomé, C, Artuch, R, Sierra, C, et al. Plasma thiols and their determinants in phenylketonuria. Eur J Clin Nutr
2003; 57: 964–968.
Mütze, U, Beblo, S, Kortz, L, et al. Metabolomics of dietary fatty acid restriction in patients with phenylketonuria. PLoS One
2012; 7: e43021.
Walter, JH, Lachmann, RH, Burgard, P. Hyperphenylalaninemia. In: Saudubray JM, van den Berge G, Walter JH (eds). Inborn Metabolic Diseases: Diagnosis and Treatment, 5th edn. Springer-Verlag, Berlin Heidelberg, 2012: 253–264.
Cole, TJ, Lobstein, T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes
2012; 7: 284–294.
National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. Pediatrics
1996; 98: 649–658.
Blau, N, van Spronsen, FJ, Levy, HL. Phenylketonuria. Lancet
2010; 376: 1417–1427.
Das, AM, Goedecke, K, Meyer, U, et al. Dietary habits and metabolic control in adolescents and young adults with phenylketonuria: self-imposed protein restriction may be harmful. JIMD Rep
2014; 13: 149–158.
Friedewald, WT, Levy, RI, Fredrickson, DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem
1972; 18: 499–502.
Jian, ZH, Chiang, YC, Lung, CC, et al. Vegetarian diet and cholesterol and TAG levels by gender. Public Health Nutr
2015; 18: 721–726.
Huang, YW, Jian, ZH, Chang, HC, et al. Vegan diet and blood lipid profiles: a cross-sectional study of pre and postmenopausal women. BMC Womens Health
2014; 14: 55.
Chiang, JK, Lin, YL, Chen, CL, et al. Reduced risk for metabolic syndrome and insulin resistance associated with ovo-lacto-vegetarian behavior in female Buddhists: a case-control study. PLoS One
2013; 8: e71799.
Bradbury, KE, Crowe, FL, Appleby, PN, Schmidt, JA, Travis, RC, Key, TJ. Serum concentrations of cholesterol, apolipoprotein A-I and apolipoprotein B in a total of 1694 meat-eaters, fish-eaters, vegetarians and vegans. Eur J Clin Nutr
2014; 68: 178–183.
Holven, KB, Aukrust, P, Retterstøl, K, et al. The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects. J Nutr
2008; 138: 2070–2075.
Castillo, M, Zafra, MF, Garcı´a-Peregrin, E. Inhibition of brain and liver 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase in experimental hyperphenylalaninemia. Neurochem Res
1988; 13: 551–555.
Yu, S, Yarnell, JW, Sweetnam, P, Bolton, CH. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis
2003; 166: 331–338.
Jacobs, DR, Mebane, IL, Bangdiwala, SI, Criqui, MH, Tyroler, HA. High density cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the lipid research clinics prevalence. Am J Epidemiol
1990; 131: 32–47.
Ware, J, Corken, A, Khetpal, R. Platelet function beyond hemostasis and thrombosis. Curr Opin Hematol
2013; 20: 451–456.
Rondina, MT, Weyrich, AS, Zimmerman, GA. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res
2013; 112: 1506–1519.
Chesnutt, JK, Han, HC. Platelet size and density affect shear-induced thrombus formation in tortuous arterioles. Phys Biol
2013; 10: 056003.
Martin, JF, Trowbridge, EA, Salmon, G, Plumb, J. The biological significance of platelet volume: Its relationship to bleeding time, thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res
1983; 32: 443–460.
Berger, JS, Eraso, LH, Xie, D, Sha, D, Mohler, ER. Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999-2004. Atherosclerosis
2010; 213: 586–591.
Chu, SG, Becker, RC, Berger, PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost
2009; 8: 148–155.
Makay, B, Turkyilmaz, Z, Unsal, E. Mean platelet volume in children with familial Mediterranean fever. Clin Rheumatol
2009; 28: 975–978.
Arslan, N, Makay, B. Mean platelet volume in obese adolescents with nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab
2010; 23: 807–813.
Arslan, N, Makay, B, Hızlı, S, et al. Assesment of atherosclerosis in obese adolescents: positive corelation of mean platelet volume and carotid intima media thickness. J Paediatr Child Health
2013; 49: 963–968.
Dolasık, I, Sener, SY, Celebi, K, Aydın, ZM, Korkmaz, U, Canturk, Z. The effect of metformin on mean platelet volume in diabetic patients. Platelets
2013; 24: 118–121.
Khode, V, Sindhur, J, Kanbur, D, Ruikar, K, Nallulwar, S. Mean platelet volume and other platelet volume indices in patients with stable coronary artery disease and acute myocardial infarction: a case control study. J Cardiovasc Dis Res
2012; 3: 272–275.
Verdoia, M, Camaro, C, Barbieri, L, et al. Mean platelet volume and the risk of periprocedural myocardial infarction in patients undergoing coronary angioplasty. Atherosclerosis
2013; 228: 136–141.
Ahluwalia, N, Blacher, J, Szabo de Edelenyi, F, et al. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis
2013; 228: 478–484.
Steed, MM, Tyagi, SC. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid Redox Signal
2011; 15: 1927–1943.
Signorello, MG, Pascale, R, Leoncini, G. Reactive oxygen species accumulation induced by homocysteine in human platelets. Ann N Y Acad Sci
2002; 973: 546–549.
Holven, KB, Aukrust, P, Pedersen, TM, Ose, L, Nenseter, MS. Enhanced platelet activation in hyperhomocysteinemic individuals. J Thromb Haemost
2007; 5: 193–195.
Becker, JS, Adler, A, Schneeberger, A, et al. Hyperhomocysteinemia, a cardiac metabolic disease: role of nitric oxide and the p22phox subunit of NADPH oxidase. Circulation
2005; 111: 2112–2118.
Vugteveen, I, Hoeksma, M, Monsen, AL, et al. Serum vitamin B12 concentrations within reference values do not exclude functional vitamin B12 deficiency in PKU patients of various ages. Mol Genet Metab
2011; 102: 13–17.
Thiele, AG, Weigel, JF, Ziesch, B, et al. Nutritional changes and micronutrient supply in patients with phenylketonuria under therapy with tetrahydrobiopterin (BH(4)). JIMD Rep
2013; 9: 31–40.
Rohde, C, von Teeffelen-Heithoff, A, Thiele, AG, et al. PKU patients on a relaxed diet may be at risk for micronutrient deficiencies. Eur J Clin Nutr
2014; 68: 119–124.